W

WuXi XDC Cayman Inc
HKEX:2268

Watchlist Manager
WuXi XDC Cayman Inc
HKEX:2268
Watchlist
Price: 26.7 HKD 6.37% Market Closed
Market Cap: 32B HKD
Have any thoughts about
WuXi XDC Cayman Inc?
Write Note

WuXi XDC Cayman Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

WuXi XDC Cayman Inc
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
W
WuXi XDC Cayman Inc
HKEX:2268
Cash & Cash Equivalents
ÂĄ4B
CAGR 3-Years
422%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Cash & Cash Equivalents
ÂĄ14.7B
CAGR 3-Years
14%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Cash & Cash Equivalents
ÂĄ2.3B
CAGR 3-Years
-19%
CAGR 5-Years
48%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Cash & Cash Equivalents
ÂĄ9.2B
CAGR 3-Years
-7%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Cash & Cash Equivalents
ÂĄ3.2B
CAGR 3-Years
-28%
CAGR 5-Years
9%
CAGR 10-Years
33%
Genscript Biotech Corp
HKEX:1548
Cash & Cash Equivalents
$1.4B
CAGR 3-Years
15%
CAGR 5-Years
39%
CAGR 10-Years
N/A
No Stocks Found

WuXi XDC Cayman Inc
Glance View

Market Cap
32B HKD
Industry
Life Sciences Tools & Services

WuXi XDC Cayman Inc is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Wuxi, Jiangsu and currently employs 1,113 full-time employees. The company went IPO on 2023-11-17. WuXi XDC Cayman Inc is a holding company primarily engaged in the provision of contract research, development and manufacturing services (CRDMO) for antibody drug conjugates (ADCs) and a wider range of bioconjugate drugs. The firm conducts its businesses through two segments. Research Services on Fee-for-service(FFS) Basis segment providing research services to its customers through FFS contracts. The Research Services on Full-time-equivalent(FTE) Basis segment providing a project team of employees dedicated to the customer's studies for a specific period of time. Based on biopharmaceuticals and small molecule drugs, the Company also provides comprehensive cross-domain services, covering the discovery, process development and good manufacturing practice (GMP) production of bioconjugated drugs, linkers and payloads. The firm conducts its business in domestic and foreign markets.

Intrinsic Value
28.5 HKD
Undervaluation 6%
Intrinsic Value
Price
W

See Also

What is WuXi XDC Cayman Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
4B CNY

Based on the financial report for Dec 31, 2023, WuXi XDC Cayman Inc's Cash & Cash Equivalents amounts to 4B CNY.

What is WuXi XDC Cayman Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 3Y
422%

Over the last year, the Cash & Cash Equivalents growth was 1 108%. The average annual Cash & Cash Equivalents growth rates for WuXi XDC Cayman Inc have been 422% over the past three years .

Back to Top